357 results about "Mucoproteins" patented technology

The invention discloses a polypeptide and application thereof in preparation of a medicine for preventing and / or treating cancers. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1 or SEQ ID No. 2. The cancer is at least one of breast cancer, colorectal cancer, leukemia, esophageal cancer, pancreatic cancer, brain glioma, kidney cancer, skin cancer, osteosarcoma, ovarian cancer and prostate cancer. The invention designs and synthesizes the polypeptide of a targeted staphylococcus tumor protein compound SND1-MTDH containing a nuclease structural domain 1 (SND1 and a heteromucin (MTDH), finds that the polypeptide has excellent inhibitory activity on various different types of human cancer cells for the first time, and provides an optional scheme for broad-spectrum anti-cancer drugs. The polypeptide applied in the invention is simple in synthesis process and low in production cost.

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention provides an antibody specifically combined with CDH6 (cadherin 6) and application thereof, and particularly discloses mouse and humanized antibodies combined with CDH6 as well as a preparation method and application thereof, and the mouse and humanized antibodies have better affinity with CDH6 protein and better endocytosis activity, so that the mouse and humanized antibodies can be applied to preparation of medicines for treating tumors and the like.

The invention discloses a polyphenol-based tissue adhesive for promoting wound healing and a preparation method thereof, and relates to the technical field of medical tissue adhesives. The preparation method of the tissue adhesive comprises the following steps: step 1, preparing a polyphenol compound and recombinant mussel mucin into a solution, and uniformly stirring for later use, namely a solution A; 2, preparing a temperature response type high polymer material into a solution for later use, namely a solution B; and 3, mixing the solution A prepared in the step 1 and the solution B prepared in the step 2, fully and uniformly mixing, shaking and centrifuging, and discarding the supernatant. By selecting the temperature response type high polymer material, the tissue adhesive is endowed with the characteristic of temperature sensitivity, so that the modulus of the adhesive at the human body temperature is improved, and the colloid contraction can further promote wound closure. The mussel mucin is introduced to stimulate collagen regeneration of the wound part, activate the immune mechanism and remodel the wound microenvironment so as to achieve the purpose of promoting healing.

The invention relates to mussel mucin-hyaluronic acid nanogel and a preparation method and application thereof and a pharmaceutical composition, and belongs to the field of biomedical materials, the structural formula of the mussel mucin-hyaluronic acid nanogel is # imgabs0 #, Mussel mucin is a mussel mucin molecule, and n is the number of repetitive units. The mussel mucin-hyaluronic acid nanogel can be swelled in a water-based medium to form a three-dimensional space net-shaped structure, pharmaceutical active molecules are better entrapped, lysine and dopa groups in the structure can be tightly combined with the surface or mucous membrane of an organism through electrostatic interaction, hydrogen-bond interaction and oxidative crosslinking, so that the bioavailability of the mussel mucin-hyaluronic acid nanogel is improved, and the bioavailability of the mussel mucin-hyaluronic acid nanogel is improved. The carrier has good biological adhesion, can prolong the residence time of the carrier on an organism or mucous membrane surface, and promotes drug absorption. The mussel mucin-hyaluronic acid nanogel can also be used as a drug storage cavern, so that the slow release effect of drugs is improved, the action time of the drugs is prolonged, and the administration frequency is reduced.

The invention relates to the technical field of collagen and mucoprotein extraction, and discloses a jellyfish extract extraction process which comprises the following steps: (1) pretreatment: mainly comprising the steps of cleaning, desalting, acid and alkali treatment, homogenization, enzymolysis, centrifugation and the like, and the specific operation is performed according to the patent (application number: CN118255872A); (2) ultrafiltration and concentration: separating the supernate obtained by pretreatment, and retaining a concentrated solution; and (3) solid drying: freeze-drying the concentrated solution to obtain a jellyfish extract solid product rich in collagen and mucoprotein. The jellyfish extract prepared by the method is a white or faint yellow solid, has no peculiar smell, is rich in collagen and mucoprotein, and is widely applied to the field of cosmetics.

The invention discloses a preparation method of high-purity recombinant mussel mucoprotein, and belongs to the technical field of recombinant protein preparation, the idea of improving target protein expression by adopting fusion protein is adopted, and fusion expression is performed on partial peptide fragments of an amino acid sequence of mytilus coruscus Mfp-3 and an amino acid sequence of common mussel preCol-D to obtain the high-purity recombinant mussel mucoprotein. The recombinant mussel mucin which is high in purity, low in endotoxin content and good in adhesion performance is obtained by combining improvement of induction, tyrosinase modification and separation and purification processes, a new thought is provided for industrial production of the recombinant mussel mucin through successful preparation of the recombinant mussel mucin, raw material support is provided for multi-field application of the recombinant mussel mucin, and the method is suitable for industrial production of the recombinant mussel mucin. The customized sequence recombinant mussel mucoprotein is prepared according to application requirements, and the application of the mussel mucoprotein in different fields is promoted.

The invention relates to the technical field of hydrogel, in particular to mussel mucoprotein loaded extracellular vesicle hydrogel as well as a preparation method and application thereof. The hydrogel is prepared by adopting a mode of combining human umbilical cord mesenchymal stem cell exosome Exo and mussel mucoprotein MAP; the method has the following advantages: 1, the wound repair effect is improved: the biological activity of the exosome Exo and the adhesion performance of the mussel mucin MAP are utilized to jointly promote the wound repair process, so that the repair effect is improved; 2, the adhesion performance is enhanced: the strong adhesion of the mussel adhesive protein MAP is utilized to ensure that the hydrogel can be tightly attached to the wound surface in a wet environment, and the dressing is prevented from falling off and infection risk; and 3, multifunctionality is realized: the composite hydrogel not only has the basic functions of promoting healing, resisting bacteria and the like, but also can transmit genetic information through exosome Exo, so that tissue regeneration and skin barrier repair are further promoted.

The invention discloses broad-spectrum universal nano-coating probiotics based on mussel mucin as well as a preparation method and application of the broad-spectrum universal nano-coating probiotics. According to the method, the deposition of the mussel mucin on the surfaces of the probiotics is accelerated by virtue of supramolecular action modes such as non-covalent bonds, hydrogen bonds and cations-pi between the mussel mucin and thalli; and positive ions are complexed and coordinated with catechol groups in mussel mucin and are driven to be self-assembled into a nano-scale aggregate, so that independent coating of the probiotics is realized. The mussel mucin nano coating provided by the invention is not only suitable for encapsulating aerobic bacteria and also has a protection effect on anaerobic bacteria, but also can realize synchronous release of probiotics. More importantly, due to the addition of the cations, the adhesion capacity of the probiotics is enhanced while the network structure density of the coating is improved, and the nano-coating probiotics with high stability and biocompatibility are obtained. The nano-coating probiotic provided by the invention is simple and efficient in preparation process, is suitable for large-scale production, and is expected to become an ideal carrier for probiotic delivery.

The present invention relates to the use of Akkermansia muciniphila in preparing a pharmaceutical composition or a health product composition for improving metabolic syndrome, wherein the Akkermansia muciniphila is Akkermansia muciniphila AM06, Akkermansia muciniphila AM02 or a combination thereof; wherein the deposit number of Akkermansia muciniphila AM06 is CGMCC No.22793, and the deposit number of Akkermansia muciniphila AM02 is CGMCC No.22794. Improving metabolic syndrome includes preventing and / or treating metabolic syndrome. In the application, the obesity degree and insulin resistance of rats can be reduced, blood pressure can be regulated, blood sugar and blood lipid metabolism can be improved, and metabolic syndrome can be effectively prevented and treated. It also relates to the use of a composition containing the Akkermansia muciniphila in preparing or using a medicine for preventing and treating metabolic syndrome or in preparing or using a health food for improving metabolic syndrome.

The invention is suitable for the technical field of gynecological gels, and provides a gynecological gel with a repairing effect. Comprising the following components in percentage by weight: 0.1%-0.5% of recombinant III type human collagen, 0.05%-0.2% of mussel mucin, 1%-3% of chitosan, 0.2%-1% of sodium hyaluronate, 2%-5% of lactobacillus fermentation product filtrate, 0.05%-0.2% of tea tree essential oil, 0.2%-0.5% of carbomer, 0.1%-0.4% of triethanolamine, 0.1%-0.2% of sodium methylparaben and the balance of purified water. The gynecological gel with the repairing effect has the excellent repairing effect, integrates multiple effects of effectively resisting bacteria and diminishing inflammation, promoting repairing of damaged vaginal mucosa, adjusting vaginal micro-ecological balance and the like, not only can efficiently inhibit growth of various pathogens, but also can remarkably promote proliferation and repairing of vaginal mucosa cells, and has the advantages that the repairing effect is good, and the repairing effect is good. The vaginal micro-ecological balance can be accurately adjusted, no stimulation is caused to vaginal mucosa, safety and reliability are achieved, and long-term use can be achieved.

The invention provides application of G3BP1 in preparation of a medicine for protecting barrier function integrity of vascular endothelial cells, and belongs to the technical field of biological medicine manufacturing. The invention provides application of G3BP1 in preparation of a medicine for protecting barrier function integrity of vascular endothelial cells. The present invention relates to G3BP1 that ensures the sustained expression of key adherent junction proteins (VE-cadherin, p120) by directly binding to and stabilizing the mRNA of these proteins; meanwhile, the G3BP1 is combined with the MYD88mRNA to promote the degradation of the MYD88mRNA, so that a permeability-promoting MYD88-ARNO-ARF6 signal channel is inhibited, especially under the condition of an inflammation period. Therefore, the G3BP1 regulates and maintains the integrity of the vascular barrier through double transcription, and a new treatment strategy is provided for damage repair of the functional integrity of the vascular endothelial cell barrier.

The invention relates to a Raman probe for detecting hydrogen sulfide as well as a preparation method and application of the Raman probe. The gold and silver nanocage (AuAg NCs) is prepared, and after the gold and silver nanocage (AuAg NCs) is modified by a Raman signal molecule 4-ethynylaniline (4EA), it is found that the AuAg-4EANCs shows the strongest Raman enhancement effect at the position of 2010 cm <-1 > located in a cell silence zone. The SERS probe with the tumor targeting capability is developed through the functional modification of a mucoprotein 1 aptamer (MUin1aptamer, MUC1Apt) and polyethylene glycol (PEG), and the SERS probe with the tumor targeting capability is further developed through the functional modification of the mucoprotein 1 aptamer (MUin1aptamer, MUC1Apt) and the PEG (Polyethylene Glycol). In the presence of hydrogen sulfide (H2S) and oxygen, Ag in AuAg-4EANCs rapidly reacts with H2S to generate Ag2S with significantly reduced Raman enhancement performance, resulting in sharp attenuation of 4EA signal intensity. And along with the increase of the H2S concentration, the generation amount of Ag2S is increased, so that a quantitative detection model dependent on the H2S concentration is established.

The present invention provides an isolated Akkermansia muciniphila strain, composition comprising the same, and use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders induced by obesity, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases, brain aging, tumors, etc. Additionally, it can be used for preventing and treating metabolic disorders after discontinuation of GLP-1 receptor agonist drugs, preventing weight rebound and blood glucose rebound, and maintaining glucose homeostasis.

The invention discloses a medical wound surface composite freeze-dried dressing and a preparation method thereof, and relates to the field of medicines. The medical wound surface composite freeze-drying dressing comprises a freeze-drying product and a solvent which are independently stored, the freeze-drying product comprises recombinant mussel mucin, recombinant collagen and a freeze-drying protective agent, and the solvent comprises an osmotic pressure regulator and water. By utilizing the synergistic effect of the recombinant collagen and the recombinant mussel mucin, the wound repair effect of the medical wound composite freeze-dried dressing is improved.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The invention discloses a rapidly cross-linked recombinant mussel adhesive protein adhesive as well as preparation and application thereof, and relates to the technical field of biological adhesives. According to the preparation method of the rapidly cross-linked recombinant mussel mucin adhesive, by changing the cross-linking mode of the recombinant mussel mucin, the dosage of the catalyst can be reduced, rapid cross-linking can be realized, and the mechanical property and viscoelasticity of the adhesive can be regulated and controlled according to requirements in the preparation process.

The invention discloses a preparation method of recombinant mussel mucin rich in dopa, and belongs to the technical field of genetic engineering. When the recombinant mussel mucoprotein is co-expressed and modified, a certain amount of modifier is fed in the induction process according to the growth of thalli and the expression condition of protein, so that on one hand, the component concentration of a co-expression modification system is controlled, and a favorable environment is provided for the recombinant tyrosinase to oxidize tyrosine into DOPA; on the other hand, an environment is created for the synthesized recombinant mussel mucin containing dopa, the situation that dopa residues are oxidized into unnecessary substances such as dopaquinone and melanin due to long co-expression modification time is avoided, glutamic acid with a certain concentration in a modification auxiliary system serves as energy supply to promote modification, and the dopa oxidation rate and modification efficiency are improved.

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and / or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and / or light chain regions of the antibodies, or antigen-binding portions thereof.

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and / or PD-L2.

The application discloses a preparation method of high-purity recombinant mussel adhesive protein and belongs to the technical field of recombinant protein preparation. The amino acid sequence of Mfp-3 of Mytilus coruscus and the partial peptide segment of the amino acid sequence of preCol-D of Mytilus edulis are fused and expressed according to the idea of improving target protein expression by using fusion protein, and the improvement of the induction, tyrosinase modification and separation and purification process is combined to obtain the recombinant mussel adhesive protein with high purity, low endotoxin content and good adhesion performance. The successful preparation of the recombinant mussel adhesive protein provides a new idea for the industrial production of the recombinant mussel adhesive protein, provides raw material support for the multi-field application of the recombinant mussel adhesive protein, realizes the preparation of the customized sequence recombinant mussel adhesive protein according to application requirements, and promotes the application of the mussel adhesive protein in different fields.

The invention discloses calculus bovis combining in-vitro cultivation and in-vivo cultivation and a preparation method. The preparation method specifically comprises the following steps: (1) preparing an escherichia coli mixed bacteria solution; (2) preparing composite mucoprotein paste; and (3) carrying out in-vivo cultivation of the calculus bovis. Bacteria are preserved in the composite mucoprotein paste, and the composite mucoprotein paste has viscosity and is used as condensation nuclei for inducing calculus bovis condensation. Compared with the traditional crystal nucleus, the scheme can better protect the activity of the strain, the effect of protecting and slowly releasing the strain is achieved by using an embedding method, and strain inactivation caused by direct contact of the strain with ox bile is avoided. The ox bile simulation liquid with the best escherichia coli amplification effect is used as a bacterial liquid amplification culture medium injected into the ox gall bladder; after the mixed solution is injected, the 10% calcium chloride solution is injected again, so that a sticky bezoar bed is formed; the bilirubin content of the prepared bezoar is greater than or equal to 30%, and the cholic acid content is greater than or Each cattle cattle yellow is greater than 8g of calculus bovis; the success rate of calculus bovis preparation is greater than 90%.

To provide a technique for reducing the count of bacteria involved in mucin decomposition within the intestine, wherein the present invention allows inhibition of growth of intestinal microbes such as Ruminococcus gnavus, which can be involved in mucin degradation; and thus, it becomes possible to reduce mucin degradation within the intestine, thereby preserving the intestinal barrier function, and contributing to the maintenance or enhancement of host health.SOLUTION: Provided is an agent that comprises agaro-oligosaccharides as an active ingredient to inhibit the growth of intestinal bacteria having, in genomic DNA, a NanA gene composed of a DNA sequence having at least 45.6% sequence identity to Sequence No. 1 (NanA gene of Ruminococcus gnavus).SELECTED DRAWING: Figure 1

The present invention relates to Akkermansia muciniphila Akk11 having the functions of regulating blood glucose and blood fat and the use thereof. Said Akkermansia muciniphila Akk11 is classified and named as Akkermansia muciniphila Akk11 with the accession number of CCTCC NO: M2024119. The strain uses mucin as the unique source of carbon element and nitrogen element, so as to control the basic regulatory systems of glucose and energy metabolism, protect the integrity of intestinal epithelial cells and mucus layers to exert a protective effect on metabolism, regulate the levels of blood glucose and blood fat, and remarkably relieve symptoms of metabolic disorders, and thus providing strategies and reference basis for the prevention and treatment of obesity.

The invention relates to the technical field of gynecological gel, and discloses gynecological gel containing recombinant mussel mucin as well as a preparation method and application of the gynecological gel. The gynecological gel containing the recombinant mussel mucin comprises the following raw material components in percentage by mass: 0.01%-50% of the recombinant mussel mucin, 0.1%-20% of a gel matrix, 0.01%-1.0% of a pH regulator, 0.05%-1% of a preservative, 0.5%-20% of a humectant, 10%-50% of a protein protective agent and the balance of water, the gel matrix comprises a thickening agent and a suspending aid, and the protein protective agent is obtained by dissolving a dispersing agent, a chelating agent and a protein stabilizer in a buffer solution. The gynecological gel provided by the invention has good film-forming property, forms a protective gel film on a vaginal wall, physically isolates the vaginal wall from external bacteria, is used for protecting gynecological mucosa and preventing colonization of pathogenic microorganisms, has good anti-inflammatory and anti-oxidation effects, and can be used for preventing or treating gynecological diseases.

The invention relates to the field of biological moisturizing, in particular to yeast-source mucoprotein with a moisturizing effect and a preparation method thereof, and the preparation method comprises a recombinant strain construction method, a fermentation production method and a separation and purification method. The mucoprotein provided by the invention has good moisturizing performance, has large-scale industrial production capacity, and has good application prospects.

The invention discloses an application of Ackermann muciniphile and an outer membrane protein Amuc1100 of Ackermann muciniphile in treatment of hypertension. The outer membrane protein Amuc1100 is a protein of which the amino acid sequence is as shown in SEQ ID NO: 4. Experiments prove that the outer membrane protein Amuc1100 can enhance the intestinal barrier function of a mouse, blood pressure is reduced by remodeling the cardiovascular system and improving the intestinal microenvironment, and the blood pressure comprises systolic pressure and diastolic pressure. The invention has important application value in prevention and / or treatment of hypertension.

The invention relates to Ackermania muciniphila and application thereof, and belongs to the technical field of microorganisms. According to the present invention, the ackermania muciniphilaSYSU-85 is adopted as the ackermania muciniphilaSYSU-85, and has been preserved in the China General Microbiological Culture Collection Center (CGMCC) on August 8, 2024, and the preservation number of the ackermania muciniphilaSYSU-85 is CGMCC NO.46070; the Ackermania muciniphila SYSU-85 disclosed by the invention is weak in dependence on mucin, grows well in a BHI culture medium added with cysteine, and is resistant to oxaliplatin. The Ackermansiella muciniphila SYSU-85 provided by the invention alleviates adverse reactions caused by oxaliplatin, and is combined with oxaliplatin or a PD-1 inhibitor to significantly slow down a tumor growth curve and significantly reduce the tumor volume, thereby improving the tumor treatment effect.

The invention relates to the technical field of medical dressings, and discloses a scar repair gel containing recombinant mussel mucin and a preparation method thereof. The scar repair gel is prepared from the following components in percentage by mass: 0.01 to 0.2 percent of recombinant mussel mucin, 0.4 to 0.8 percent of a thickening agent, 6 to 15 percent of a compound emulsifier, 1 to 2 percent of a pH regulator, 20 to 40 percent of silicone, 0.1 to 0.3 percent of a preservative and the balance of water, wherein the silicone comprises polydimethylsiloxane, a polydimethylsiloxane cross-linking agent and decamethylcyclopentasiloxane. The scar repair gel containing the recombinant mussel mucin has good film-forming property, forms a moisturizing barrier on the surface of a wound, can inhibit formation of hyperplasia scars, reduces pruritus in the wound healing process, reduces generation and deposition of melanin, and has the effects of repairing scars and repairing scars. The comfort of a patient in the use process and the compounding stability of the mussel mucin and silicone gel system are effectively improved.